Core Viewpoint - The company has announced the establishment of an industrial fund to enhance strategic development and capitalize on investment opportunities in the biopharmaceutical sector [1] Group 1: Investment Details - The company will collaborate with Guangzhou Nanyue Aoyang Fund Management Co., Ltd. and Guangzhou Nanyue Fund Group Co., Ltd. to set up the Guangzhou Zengcheng Nante Biopharmaceutical Investment Partnership (Limited Partnership) [1] - The total investment amount for the industrial fund is RMB 50.01 million, with the company contributing RMB 25 million, accounting for 49.99% of the total subscription [1] - The fund will primarily invest in early and mid-stage biopharmaceutical projects [1] Group 2: Regulatory Compliance - The investment partnership has completed the filing procedures with the Asset Management Association of China and has obtained the Private Investment Fund Filing Certificate [1]

Core Insights - The company reported a revenue of 398 million yuan for the first three quarters of 2025, representing a year-on-year growth of 1.88% [1] - The net profit attributable to the parent company reached 57.29 million yuan, showing a year-on-year increase of 14.22% [1] - The net profit excluding non-recurring items was 53.16 million yuan, reflecting a year-on-year growth of 20.71% [1]

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-065 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于对外投资设立产业基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、对外投资设立产业基金概述 广州洁特生物过滤股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日召 开第四届董事会第二十一次会议，审议通过了《关于拟对外投资设立产业基金的 议案》。为深化落实公司战略发展规划，加深产业资本合作，借助专业投资机构 的力量及资源优势通过股权投资进一步发掘具有产业协同效应的优质项目，助力 公司长远发展，公司与广州南粤澳洋基金管理有限公司（以下简称"南粤澳洋"）、 广州南粤基金集团有限公司（以下简称"南粤基金"）出资发起设立广州增城区 南特生物医药投资合伙企业（有限合伙）（以下简称"南特投资"），主要投资 于早、中期生物医药类项目，产业基金总出资额为人民币 5,001 万元，其中公司 作为 ...

Financial Performance - The company's operating revenue for the third quarter was ¥130,039,526.89, a decrease of 15.87% compared to the same period last year[3]. - Total profit for the quarter was ¥12,494,752.97, down 48.16% year-on-year[3]. - Net profit attributable to shareholders was ¥10,952,688.00, reflecting a decline of 45.66% compared to the previous year[3]. - The basic earnings per share for the quarter was ¥0.08, a decrease of 55.56% year-on-year[3]. - Total operating revenue for the first three quarters of 2025 reached ¥398,180,432.24, a slight increase from ¥390,816,368.30 in the same period of 2024, representing a growth of approximately 0.93%[19]. - The net profit for the first three quarters of 2025 reached ¥58,625,749.54, an increase of 16.5% compared to ¥50,337,922.51 in the same period of 2024[20]. - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.42, slightly up from ¥0.41 in the same period of 2024[20]. Research and Development - Research and development expenses totaled ¥7,784,426.48, accounting for 5.99% of operating revenue, an increase of 1.75 percentage points[4]. - Research and development expenses increased to ¥21,096,099.18 in 2025 from ¥19,834,731.06 in 2024, marking an increase of about 6.4%[19]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥128,296,599.37, a significant increase of 1,268.59% compared to the previous year[3]. - Cash and cash equivalents as of September 30, 2025, amounted to ¥438,226,897.19, up from ¥284,205,896.01 at the end of 2024, representing a growth of approximately 54.3%[14]. - Total assets at the end of the reporting period were ¥1,748,226,296.50, representing a 2.71% increase from the end of the previous year[4]. - Total assets as of September 30, 2025, were ¥1,748,226,296.50, compared to ¥1,702,023,099.33 at the end of 2024, showing an increase of approximately 2.7%[15]. - The company's retained earnings increased to ¥513,013,576.86 in 2025 from ¥465,769,398.40 in 2024, reflecting a growth of approximately 10.1%[16]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,274[9]. - The largest shareholder, Yuan Jianhua, holds 41,072,020 shares, representing 29.26% of total shares[9]. - JET (H.K.) BIOSCIENCE holds 17,547,293 shares, accounting for 12.50% of total shares[9]. - The company has a total of 10 major shareholders, with the top 10 holding significant stakes in the company[10]. Legal Matters - The company is involved in a lawsuit with Shanghai You Electronic Technology Co., Ltd. regarding a contract dispute, with a claim amount of RMB 18,441,691.80 and a penalty of RMB 1,386,000[11]. - The court ruled that Shanghai You must return RMB 11,256,957.82 to the company and pay a penalty of RMB 922,084.59[11]. - The company is also in a legal dispute with Shenzhen Hesheng Medical Technology Co., Ltd. over a mold procurement contract, with a claim amount of RMB 10,340,829.00 and damages of RMB 644,911[12]. - The court ordered Hesheng Medical to return the claimed amount and compensate for damages, but Hesheng Medical has appealed the decision[12]. - The company has had part of its funds frozen amounting to RMB 11,473,149.78 due to ongoing litigation[13]. - The company is actively managing its legal disputes to mitigate financial impacts and protect shareholder interests[11]. Operating Costs - Total operating costs for the first three quarters of 2025 were ¥340,567,157.86, compared to ¥329,050,630.04 in 2024, indicating an increase of about 3.8%[19]. - The total cash outflow from operating activities in the first three quarters of 2025 was ¥392,674,512.47, a decrease from ¥423,922,874.13 in the same period of 2024[22].

Group 1 - The company announced the establishment of an industrial fund named Nantou Investment, in collaboration with Nanyue Aoyang and Nanyue Fund, focusing on early and mid-stage biopharmaceutical projects [1] - The total investment amount for the industrial fund is 50.01 million yuan, with the company committing 25 million yuan, accounting for 49.99% of the fund [1] - Nantou Investment has completed the filing procedures with the Asset Management Association of China and obtained the Private Investment Fund Filing Certificate [1]

Core Viewpoint - The company announced the final judgment of a lawsuit involving its wholly-owned subsidiary, which may have uncertain impacts on its financials due to the execution of the judgment [1][4]. Group 1: Lawsuit Background - The lawsuit originated from a dispute between the company's subsidiary, Guangzhou Baifeier Air Purification Materials Co., Ltd. (Baifeier), and Shanghai Deyou Electronic Technology Co., Ltd. regarding contracts for PTFE nano films needed for mask production [2]. - The initial claim involved a total amount of 18,441,691.80 yuan for goods and 1,386,000.00 yuan in penalties [2]. Group 2: Second Instance Judgment - The second-instance court partially upheld the appeal from Shanghai Deyou, correcting the first-instance judgment [3]. - The court ordered Shanghai Deyou to refund 11,256,957.82 yuan to Baifeier within ten days of the judgment's legal effect [3]. - The original defendant, Liu Keping, is held jointly liable for the debt [3]. Group 3: Financial Implications - The company has already made full provisions for bad debts related to the prepayments to Shanghai Deyou and for the inventory of PTFE nano films [4]. - Despite the final judgment, there remains uncertainty regarding the execution of the judgment and the potential recovery of the involved amount, which could affect the company's profits [4].

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-064 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 二、本次诉讼二审终审判决情况 广州洁特生物过滤股份有限公司 关于全资子公司诉讼事项二审判决结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任 重要内容提示： 一、本次诉讼的基本情况 广州洁特生物过滤股份有限公司（以下简称"公司"）全资子公司广州拜费尔 空气净化材料有限公司（以下简称"拜费尔"）与上海的优电子科技有限公司（以 下简称"上海的优"）分别于 2020 年 5 月 13 日和 2020 年 9 月 18 日签订了生产口 罩所需的原材料 PTFE 纳米薄膜的《购销合同》和《补充协议》，拜费尔就《购 销合同》及《补充协议》纠纷一案向广州市黄埔区人民法院（以下简称"黄埔法 院"）起诉上海的优、刘客平、李优红，诉讼涉案金额为货款 18,441,691.80 元 以及违约金 1,386,000.00 元。 2024 年 8 月，黄埔法 ...

Core Insights - Jiet Bio's stock increased by 5.45% to 19.14 CNY per share, with a trading volume of 36.47 million CNY and a turnover rate of 1.40%, resulting in a total market capitalization of 2.687 billion CNY [1] Company Overview - Guangzhou Jiet Biofilter Co., Ltd. is located in the Yonghe Economic Zone of Guangzhou, Guangdong Province, established on April 11, 2001, and listed on January 22, 2020 [1] - The company's main business involves the research, development, production, and sales of disposable plastic consumables for biological laboratories related to cell culture and liquid handling [1] - Revenue composition: Liquid handling accounts for 60.24%, cell culture for 30.74%, other supplementary products for 4.98%, and instruments and other categories for 4.04% [1] Shareholder Information - Among the top ten circulating shareholders of Jiet Bio, one fund from Huaxia Fund, Huaxia CSI 500 Index Enhanced A (007994), has entered the list, holding 1.1212 million shares, which is 0.8% of the circulating shares [2] - The estimated floating profit for this fund today is approximately 1.11 million CNY [2] - Huaxia CSI 500 Index Enhanced A was established on March 25, 2020, with a latest scale of 3.135 billion CNY, and has achieved a year-to-date return of 22.68% [2] Fund Manager Performance - The fund manager of Huaxia CSI 500 Index Enhanced A is Sun Meng, who has been in the position for 5 years and 220 days [3] - The total asset scale of the fund is 10.461 billion CNY, with the best return during the tenure being 126.46% and the worst return being 17.83% [3]

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-063 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本季度转股情况：公司向不特定对象发行可转换公司债券证券"洁特转 债"自 2023 年 1 月 4 日起可转换为公司股份。自 2025 年 7 月 1 日至 2025 年 9 月 30 日期间，"洁特转债"共有人民币 54,000 元已转换为公司股票，转股数量 为 1,125 股，占"洁特转债"转股前公司已发行股份总额的 0.0008%。 ● 累计转股情况：截至 2025 年 9 月 30 日，"洁特转债"累计有人民币 57,000 元已转换为公司股票，转股数量为 1,185 股，占"洁特转债"转股前公司已发行 股份总额的 0.00084%。 ● 未转股可转债情况：截至 2025 年 9 月 30 日，"洁特转债" ...

Group 1 - The core viewpoint of the article highlights the target price increases for several listed companies, with notable gains for Dongcai Technology, Seres, and Gree Electric, showing target price increases of 51.97%, 37.62%, and 36.96% respectively [1][3] - On September 25, a total of 12 target price adjustments were made by brokerages, with the highest target price set at 32.43 yuan for Dongcai Technology [1][3] - A total of 35 listed companies received brokerage recommendations on September 25, including Sanyuan Shares, Anhui Weaving High-tech, and Yixin Pharmacy [1][3] Group 2 - On the same date, two companies had their ratings upgraded, with Renfu Pharmaceutical's rating raised from "Hold" to "Buy" by Shouchuang Securities, and Sanhuan Group's rating upgraded from "Hold" to "Buy" by Huazheng Securities [4][6] - A total of 10 companies received initial coverage from brokerages, with Frontier Biotech receiving a "Buy" rating from Kaiyuan Securities and Jiete Biotech also receiving a "Buy" rating from Xinda Securities [4][7] - Other companies receiving initial coverage include Bowei Alloy with a rating of "Hold" and Leisai Intelligent with a "Buy" rating, indicating a diverse range of sectors being covered [4][7]